The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The TOURMALINE-MM1 study: subgroup analysis via prior therapy
A subgroup analysis of the TOURMALINE-MM1 was published on 27th July 2017 in Haematologica. The study was led by Maria Victoria Mateos, from the Hospital Universitario de Salamanca, Spain, and a member of the MM Hub Steering Committee. The authors investigated the effect of previous therapies on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-lenalidomide-dexamethasone (placebo-Rd), in patients with Relapsed/Refractory Multiple Myeloma (RRMM). A summary of the TOURMALINE-MM1 study key highlights and results were reported in a previous MM Hub article.
Study Highlights
- Patients (pts) included in the study = 722 pts
- Subgroups analyzed:
- Type of previous therapy: proteasome inhibitor (PI) (n = 503) and immunomodulatory drug (IMiD) (n = 397)
- Number of previous therapies: 1 (n = 425) vs 2 or 3 (n =297)
Key Findings
- Median follow-up = 15 months
- Median Progression Free Survival (PFS) showed better clinical benefit with ixazomib-Rd vs placebo-Rd regardless of previous therapy type:
- PI-exposed pts = 18.4 vs 6 months (HR = 0.739)
- PI-naïve pts = not reached vs 7 months (HR = 0.749)
- IMiD-exposed pts = not reached vs 5 months (HR = 0.744)
- IMiD-naïve pts = 20.6 vs 6 months (HR = 0.700)
- Median Time To Progression (TTP) was also longer with ixazomib-Rd vs placebo-Rd regardless of previous therapy type:
- PI-exposed pts = 18.5 vs 9 months (HR = 0.702, 95% CI 0.526, 0.936)
- PI-naïve pts = not estimable vs 5 months (HR = 0.741, 95% CI 0.456, 1.203)
- IMiD-exposed pts = not estimable vs 3 months (HR = 0.727, 95% CI 0.515, 1.026)
- IMiD-drug-naïve pts = 20.6 vs 6 months (HR = 0.651, 95% CI 0.449, 0.945)
- PFS and TTP was prolonged for ixazomib-Rd vs placebo-Rd in pts with 1, 2 or 3 prior therapies
- PFS 1 vs 2 or 3 prior therapies = HR = 0.88 (95% CI: 0.65–1.20) vs 58 (95% CI: 0.40–0.84)
- TTP 1 vs 2 or 3 prior therapies = HR = 0.842 (95% CI 0.614, 1.156) vs 550 (95% CI 0.370, 0.819)
Safety
- Median follow-up = 23 months
- Toxicity findings were similar across all subgroups
- Higher rates of grade ≥3 Adverse Events (AE) and serious AEs were seen in the placebo-Rd subgroup and in pts who had 2 or 3 previous therapies
Conclusion
This efficacy study showed that PFS and TTP was prolonged with ixazomib-Rd treatment, but that there was no specific correlation with prior treatment with a PI, IMiD or the number of previous treatments received. Safety profiles showed no additional toxicity concerns amongst the subgroups. The study subgroup analysis further confirmed the positive results of using ixazomib-Rd in RRMM therapy as demonstrated in the TOURMALINE-MM1 study.
References